The study, conducted by Nasim Sadat Hosseini Divkolaye of the Iranian Blood Transfusion Organization and the Blood Transfusion Research Center in Tehran, was published as an open access review on 5 September 2026. A scoping review design was chosen deliberately because the relevant evidence is heterogeneous in study design, methodology, and outcome measures. Rather than pooling effect sizes, the approach maps the breadth of available evidence. The author searched PubMed/MEDLINE, Scopus, Web of Science, and ScienceDirect, complemented by grey literature including World Health Organization Regional Office reports, Arab Barometer surveys, and national blood service sources, with the final search completed in November 2025. Sources were screened against predefined eligibility criteria, data were charted and synthesized thematically following Joanna Briggs Institute methodology, and the review was reported in accordance with the PRISMA Extension for Scoping Reviews. Social determinants of health and capability frameworks guided the synthesis.

The technical core of the review is a comparative argument. Anemia, defined by low hemoglobin concentration, is the most common medical reason for deferring female donors, and the included evidence consistently reported higher female deferral rates attributed to this cause. But the review demonstrates that deferral statistics cannot explain the magnitude of the participation gap. The median female share of donations in the Eastern Mediterranean sits at roughly six percent, while women globally contribute close to one-third of donations. Regions where anemia is more prevalent still manage to recruit female donors at far higher rates. The arithmetic is simple: if anemia alone determined who donates, the Eastern Mediterranean should not sit at the bottom of the distribution while less iron-replete populations donate more. Something else is operating, and the review identifies it in the social and structural environment surrounding the donation decision.

That something, the review finds, begins with gendered norms and household dynamics. Women across the region reported strong altruistic intentions toward donation, yet described intersecting constraints that made acting on those intentions difficult. Unpaid care burdens consumed the time and flexibility that donation requires. Mobility limits restricted independent travel to donation sites. Restrictive social norms framed the act of giving blood as incompatible with expectations placed on women. Family gatekeeping emerged as a recurring theme, with relatives exercising effective veto power over a woman’s decision to donate. These are not marginal frictions; they are structural constraints embedded in daily life, and they operate before any donor ever reaches a clinic door or a hemoglobin test.

The second layer of the problem lies in how blood services themselves are designed. Across studies, the review reported system-level factors that effectively screen women out. Donation infrastructure in the region skews toward fixed sites with male-oriented service design, and mobile collection units are limited, which matters enormously for potential donors whose mobility is already constrained. Family replacement practices, in which patients must recruit donors from their own networks, interact with gendered household power to further reduce women’s participation. Recruitment and retention strategies were described as gender-blind, failing to account for the different circumstances of female donors. Digital divides limited access to appointment systems and information channels. Perhaps most fundamentally, the review highlighted a lack of sex-disaggregated data, which means blood services often cannot even see the scale or shape of the gender gap they are perpetuating.

The analytical lens the review proposes is drawn from capability theory and social determinants of health research. In this framing, the relevant question is not whether an individual woman has sufficient hemoglobin on a given day, but whether she possesses the real freedom to participate in donation at all. Capability depends on the interaction of biomedical factors with resources, norms, institutional design, and political economy. A woman with adequate iron stores who cannot travel to a donation center, cannot negotiate permission from family members, and faces a clinic designed around male donors is, in practical terms, excluded. The review argues that this structural lens better explains the persistence of the gap than models centered on individual biomedical deficits, and it reframes low female participation as an equity problem rather than a physiology problem.

The implications for blood system sustainability in the region are considerable. Blood supplies depend on voluntary, repeat donors, and excluding half the population from the donor pool places chronic strain on transfusion services. The review’s findings are consistent with the interpretation that closing the gap requires more than iron supplementation campaigns or donor education. The author proposes gender-responsive service design, meaning collection systems built around the realities of women’s lives, including expanded mobile units and female-appropriate facilities. Routine sex-disaggregated data collection is identified as a foundational step, since services cannot manage what they do not measure. Structural reforms that expand women’s capability to participate, addressing care burdens, mobility, and gatekeeping, are presented as necessary conditions for any durable change.

The review also carries a methodological message for the field. Because the evidence base is fragmented across study designs and outcome measures, and because sex-disaggregated donation data are scarce, the true scope of the problem is difficult to quantify precisely. The scoping review format is honest about this limitation: it maps what is known rather than estimating pooled effects. Yet the consistency of the findings across heterogeneous sources, from peer-reviewed studies to WHO reports to population surveys, strengthens the central claim. The convergence of comparative epidemiology, qualitative accounts of women’s experiences, and health system analysis points in the same direction, toward structural explanation.

What makes this study resonate beyond transfusion medicine is its broader argument about how health inequities hide behind biomedical explanations. Attributing low female donation to anemia individualizes a problem that is actually produced by institutions and norms, and it quietly absolves health systems of responsibility for redesign. The review’s comparative data dismantle the anemia narrative on its own terms, and its synthesis of social and structural determinants offers a testable alternative. If blood services in the Eastern Mediterranean adopt gender-responsive design, collect disaggregated data, and reform the practices that constrain women’s participation, the resulting changes in donation rates would provide a natural experiment on the review’s central claim. For now, the study stands as a documented case of a health system outcome shaped less by biology than by the structures surrounding it, and a warning that sustainable blood supplies in the region may depend on closing a gender gap that medicine alone cannot fix.

Subject of Research: Gendered social and structural determinants of women's blood donation in the Eastern Mediterranean Region

Article Title: Beyond anemia: gendered social and structural determinants of women’s blood donation in the Eastern Mediterranean Region: a scoping review

Article References: Divkolaye, N. S. H. (2026). Beyond anemia: gendered social and structural determinants of women’s blood donation in the Eastern Mediterranean Region: a scoping review. International Journal for Equity in Health. https://doi.org/10.1186/s12939-026-03011-w

Image Credits: AI Generated

DOI: 10.1186/s12939-026-03011-w

Keywords: blood donation, women, gender equity, Eastern Mediterranean Region, anemia, structural determinants, health systems, social norms, scoping review, donor deferral, hemoglobin, civic participation

The biological logic underlying these findings is straightforward but worth restating. HPV vaccines are prophylactic: they prevent new infection with vaccine-covered oncogenic types, chiefly HPV16 and HPV18, but they do not treat infection that is already established or lesions that already exist. Maximum impact is therefore expected when vaccination is delivered before any sexual exposure to the virus. This principle explains the consistent age gradient seen across national studies, in which protection is strongest among women vaccinated in early adolescence and weaker or less precise among those vaccinated later through catch-up programmes. The causal sequence runs from reduced vaccine-type infection, to fewer persistent infections, to fewer high-grade cervical precancerous lesions classified as CIN2+ or CIN3, to fewer invasive cancers, and ultimately to fewer deaths.

Before mortality data existed, each link in that chain had already been forged. Surveillance in the United States documented declines in vaccine-type HPV prevalence among females aged 14 to 19 within several years of vaccine introduction, with continued reductions and evidence of herd protection in subsequent analyses. A landmark meta-analysis by Drolet and colleagues demonstrated substantial population-level reductions in HPV16/18 infection, anogenital warts, and CIN2+ after vaccination programmes were implemented, particularly where coverage was high and multiple age cohorts were vaccinated. National registry studies then moved the endpoint to invasive cancer itself: in Sweden, quadrivalent vaccination was associated with sharply lower cervical cancer risk, strongest among women vaccinated before age 17; Danish data showed high effectiveness among those vaccinated before age 20; English register-based studies found large reductions in cervical cancer and CIN3, greatest in cohorts offered routine vaccination at ages 12 to 13, with benefits extending across socioeconomic groups; and Scotland reported no invasive cervical cancer cases among women immunized at ages 12 to 13.

The new mortality milestone comes from Sasieni and Falcaro, who analyzed population-based cervical cancer mortality in England from 2001 through 2024 among women aged 20 to 24, 25 to 29, and 30 to 34 years. Vaccination coverage by birth cohort was drawn from official reports, and Poisson regression was applied to death counts to estimate the reduction associated with vaccination compared with a modeled counterfactual based on historical mortality patterns, assuming no herd immunity. The most highly vaccinated routine cohort, women aged 20 to 24 in 2020 to 2024, produced the strongest mortality signal, with zero observed deaths. Earlier catch-up cohorts also showed substantial reductions at ages 20 to 24 and 25 to 29, while the estimate at ages 30 to 34 was considerably less precise. This gradient is biologically coherent: the youngest cohorts were vaccinated earliest, at the highest coverage, and were least likely to have been exposed to oncogenic HPV before immunization.

The authors of the review are careful to appraise the England study critically rather than celebrate it uncritically. Its strengths are considerable: national population coverage, long-term mortality ascertainment, a birth-cohort framework, temporal alignment with the 2008 vaccination programme, and results that fit seamlessly with the earlier reductions in infection, CIN3, and invasive cancer. The principal limitation, however, is the modeled counterfactual. Expected deaths were extrapolated from historical pre-vaccination mortality patterns rather than observed in a contemporaneous unvaccinated control group, so secular changes in screening, diagnostics, treatment, or death certification could in principle influence the trends. Such confounding is unlikely to be fully eliminated in any observational design, even when the timing and birth-cohort pattern align with vaccination.

A second and subtler limitation concerns the very small absolute number of deaths at young ages. In the most protected cohort, the modeled counterfactual amounted to only a few dozen deaths over five years. With zero observed deaths, the point estimate for relative reduction necessarily reaches 100 percent, regardless of whether the true underlying mortality rate is exactly zero or merely very low. The absolute comparison and its confidence interval are therefore more informative than the headline percentage. The absence of deaths is clinically striking, but it should not be read as proof that an individual vaccinated woman has zero risk of dying from cervical cancer. Nor does the study provide individual-level causal inference: vaccination status, screening history, HPV exposure, socioeconomic factors, and treatment pathways were not jointly linked for every death, so the findings support a programme-level conclusion rather than a personal risk estimate.

Screening context adds important nuance to the interpretation. The English cervical screening programme targets ages 25 to 64, with first invitations issued from age 24 years and 6 months, so screening exposure in the 20-to-24-year mortality group was limited to the oldest fraction of that band. This makes screening an unlikely explanation for the mortality pattern in the youngest cohort. For women aged 25 and older, however, screening is a potential co-determinant of mortality that must remain part of the picture. National coverage at 31 March 2024 stood at 68.8 percent among those aged 25 to 64 and 66.1 percent among those aged 25 to 49, with the lowest coverage in the 25-to-29-year subgroup, and the mortality analysis did not directly adjust for individual screening participation. Vaccination remains the most coherent explanation for the birth-cohort gradient, but screening and treatment should be regarded as complementary contributors rather than ignored confounders.

The review also emphasizes that the England results are as much a triumph of programme delivery as of vaccine efficacy. The routine cohorts that generated the strongest mortality effect had adolescent coverage of roughly 88 to 90 percent, whereas more recent single-dose coverage among English year-10 students has slipped to 75.5 percent for girls and 70.5 percent for boys in the 2024 to 2025 academic year. Sustained declines in uptake could erode both direct protection and herd effects in future cohorts. Equity is equally central: coverage must be monitored by geography, deprivation, school attendance, and migration status, because lower uptake in specific subgroups can preserve pockets of preventable disease even when national averages look favorable. On safety, common adverse effects such as injection-site pain, dizziness, nausea, and headache are generally mild, and WHO safety reviews have not supported a causal association between HPV vaccination and infertility.

The global implications are framed through the World Health Organization’s 90-70-90 elimination strategy, which targets 90 percent of girls fully vaccinated by age 15, 70 percent of women screened with a high-performance test at ages 35 and 45, and 90 percent of women with precancer or invasive cancer appropriately treated. Yet the review’s regional analysis shows how unevenly these tools are distributed. In the WHO Eastern Mediterranean Region, an estimated 16,833 new cervical cancer cases and 10,704 deaths occurred in 2022, and a 2026 regional review found that only eight of 22 countries had national HPV vaccination programmes while only seven reported cervical screening programmes, all opportunistic and cytology-based. Qatar illustrates the implementation gap: GLOBOCAN 2024 estimated 37 new cases and 13 deaths there, HPV vaccination was approved only in May 2023 as an optional offering, and no robust national coverage estimate exists. Among 398 university students surveyed in Doha, just 6.3 percent reported prior vaccination, though 71 percent of unvaccinated students said they would accept the vaccine if a healthcare professional recommended it, and a survey of 557 Qatari physicians identified limited public awareness and reluctance to discuss sexual health as key barriers.

The durable message of the review is broader than any single zero-death observation. Vaccinate early, maintain high and equitable coverage, continue appropriate cervical screening, treat precancer and cancer promptly, and monitor outcomes by age, geography, and socioeconomic indicators over decades. The strongest current mortality evidence comes from young cohorts in whom absolute deaths are rare and expected deaths are modeled from historical trends, and the effect on mortality after age 40, when cervical cancer deaths become more common, remains unknown and will require long follow-up. England’s ambition to eliminate cervical cancer by 2040 shows how vaccination, screening, and treatment can be organized toward a common endpoint, but the English mortality estimates should be understood as evidence of achievable population benefit under high-coverage conditions, not as a numerical forecast that any country can simply import. HPV vaccination has now progressed convincingly from preventing infection, to preventing cancer, to preventing death at the population level, and the task ahead is to make that progression possible everywhere.

Subject of Research: Population-level evidence linking prophylactic HPV vaccination to the prevention of cervical cancer mortality

Article Title: HPV vaccination and cervical cancer deaths: from incidence reduction to mortality prevention

Article References: Alkhanafsa, M., Wafi, J., Deek, S., & Abdalhadi, A. (2026). HPV vaccination and cervical cancer deaths: from incidence reduction to mortality prevention. Clinical Cancer Bulletin, 5(1), Article 22. https://doi.org/10.1007/s44272-026-00074-2

Image Credits: AI Generated

DOI: 10.1007/s44272-026-00074-2

Keywords: HPV vaccination, cervical cancer, cervical cancer mortality, HPV16, HPV18, cervical screening, CIN3, WHO 90-70-90 targets, cancer elimination, England HPV programme, Eastern Mediterranean Region, vaccine coverage